GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline

pharmanewsdaily- February 10, 2019 0

GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused biopharmaceutical company based in Waltham, Massachusetts. This ... Read More

Pfizer’s Vizimpro receives EMA approval recommendation for NSCLC treatment

pharmanewsdaily- February 3, 2019 0

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a significant boost to Pfizer's lung cancer drug, Vizimpro (dacomitinib), ... Read More

Lilly to acquire Loxo Oncology in $8bn deal: A game-changer in precision cancer treatment

pharmanewsdaily- January 13, 2019 0

Eli Lilly and Company (Lilly), a global leader in pharmaceuticals, has made headlines with its announcement to acquire Loxo Oncology, a pioneering biopharmaceutical company based ... Read More

Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities

pallavi123- December 23, 2018 0

Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for ... Read More

Brooklyn Immuno Therapeutics acquires IRX Therapeutics’ assets for cytokine-based cancer therapy

pharmanewsdaily- November 19, 2018 0

Brooklyn Immuno Therapeutics, a New York-based clinical-stage biopharmaceutical company specializing in cytokine-based cancer therapies, has announced the acquisition of IRX Therapeutics' assets. The terms of ... Read More

Seattle Genetics’ Adcetris receives FDA approval for peripheral T-cell lymphoma

pharmanewsdaily- November 18, 2018 0

Seattle Genetics' Adcetris, in combination with CHP chemotherapy, gains FDA approval for treating certain types of peripheral T-cell lymphoma. Seattle Genetics has announced that the ... Read More

Novartis to expand radiopharmaceuticals portfolio with $2.1bn Endocyte acquisition

pharmanewsdaily- October 21, 2018 0

Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s ... Read More

AstraZeneca secures FDA approval for Lumoxiti in hairy cell leukemia treatment

pharmanewsdaily- September 14, 2018 0

AstraZeneca has achieved a major regulatory milestone with the US Food and Drug Administration (FDA) approval of Lumoxiti (moxetumomab pasudotox-tdfk), a CD22-directed cytotoxin for the ... Read More

Merck secures EC approval for Keytruda in combination therapy for lung cancer

pharmanewsdaily- September 12, 2018 0

Merck has achieved a significant milestone by obtaining approval from the European Commission (EC) for its cancer immunotherapy, Keytruda (pembrolizumab), to be used in combination ... Read More

Alkermes expands Phase 1 trial of ALKS 4230 in combination with KEYTRUDA for advanced solid tumors

pharmanewsdaily- September 11, 2018 0

Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ... Read More